NICE gives final nod to Novartis, Forest CF drugs; Sinopharm aims for $515M stock offering;

@FiercePharma: Conquering the complexities of biologics to get to biosimilars. Special report | Follow @FiercePharma

@EricPFierce: Alexion files 8-K saying FDA is not impressed with its manufacturing at its Rhode Island plant. 8-K filing | Follow @EricPFierce

> U.K. cost-effectiveness watchdogs gave their final approval to cystic fibrosis drugs from Novartis ($NVS) and Forest Laboratories ($FRX). Report

> China's biggest drug distributor, Sinopharm, plans to raise up to $515 million by selling Hong Kong shares, aiming to expand its distribution and retail network. Report

> Pfizer ($PFE) settled a lawsuit with a Boulder, CO, couple who had sued over the death of their dog, Sophie, which was given the drug Rimadyl after surgery. Report

> Novartis will sell off part of its stake in an Indian subsidiary to meet Securities and Exchange Board requirements for minimum public shareholding in listed companies. Report

Medical Device News

 @FierceMedDev: CMO adds 200 medical device jobs in Ireland. Report | Follow @FierceMedDev

 @MarkHFierce: A new FMD feature--this week in FDA med tech violations, the device industry's police blotter. More | Follow @MarkHFierce

 @DamianFierce: Abbott won the FDA's OK for a diagnostic that detects birth defects and testicular cancer progress. News | Follow @DamianFierce

> U.K.'s Consort Medical mulls Dx expansion. Report

> Bacterin 2012 revenue climbs but losses also grow. Item

Biotech News

 @FierceBiotech: From FierceBiotechResearch.com: New drug could combat resistant #malaria strains. Story | Follow @FierceBiotech

@JohnCFierce: 3 yrs after its first CRL, A.P. Pharma gets another. Insists it can do a quick turnaround, but wrong again on FDA: News | Follow @JohnCFierce

@RyanMFierce: With big RNA deal, AstraZeneca's Soriot signals yen for risky science. More | Follow @RyanMFierce

> Connecticut pols stunned as Pfizer brings in the wrecking ball. Item

> Repros shares boom on promising PhIII results for testosterone drug. Report

> Biogen Idec rolls up FDA OK for blockbuster multiple sclerosis drug Tecfidera. News

Vaccines News

> GSK vaccine plant helps U.S. arm for biodefense. Report

> Taboo topics: Sex, politics, religion... and vaccines? Article

> Swedish study adds to data linking GSK vax to narcolepsy. Item

> FDA moves decision day for GSK pandemic vaccine, but why? More

Pharma Manufacturing News

> Alexion gets warning letter for Soliris plant. Report

> FDA lifts ban on some Aurobindo antibiotics. News

> Injection point: BD, Teva, Hikma target sterile injectables. Story

> GSK gets OK for $91M vaccine plant with Texas A&M. Article

And Finally... Is modern life too cozy for our inborn survival instincts? Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.